We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Single and Multiple-Dose Study of SB1578

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01235871
Recruitment Status : Completed
First Posted : November 7, 2010
Last Update Posted : April 20, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of SB1578 in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: SB1578 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB1578 When Administered Orally to Healthy Adult Subjects With One Single-Dose Group Crossing Over to Assess Food Effect
Study Start Date : August 2010
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Experimental: SB1578 Drug: SB1578
JAK2 Inhibitor

Placebo Comparator: Placebo Drug: Placebo
Control arm

Primary Outcome Measures :
  1. Assess number of participants with adverse events as a measure of safety and tolerability [ Time Frame: 312 hours postdose ]

Secondary Outcome Measures :
  1. Assess pharmacokinetics to determine study drug half-life, maximum concentration time, elimination time, and area under the curve [ Time Frame: Predose to 312 hours postdose ]
  2. Assess pharmacodynamics to determine study drug levels to signal pJAK2, pSTAT3, and pSTAT5 [ Time Frame: Predose, 6 and 24 hours postdose ]
  3. Assess food effects on pharmacokinetics [ Time Frame: Predose to 312 hours postdose ]
  4. Determine recommended dose [ Time Frame: March 2011 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adult males and/or females of non-childbearing potential, 18 to 55 years of age (inclusive).
  • Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55 and 100 kg (inclusive).
  • Medically healthy with clinically insignificant screening results.

Exclusion Criteria:

  • History or presence of significant disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01235871

Layout table for location information
United States, Arizona
Tempe, Arizona, United States, 85283
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Mark J Allison, MD Celerion
Layout table for additonal information
Responsible Party: S*BIO
ClinicalTrials.gov Identifier: NCT01235871    
Other Study ID Numbers: SB1578-2010-001
First Posted: November 7, 2010    Key Record Dates
Last Update Posted: April 20, 2012
Last Verified: April 2012
Keywords provided by S*BIO: